We are thrilled to share that Beam has been named to TIME's list of 10 most influential health & life science companies of 2026! Thank you to the #BeamTeam for making this possible with your dedication, innovation, and passion for our patients. View the full list here: https://lnkd.in/e7adG8m4 #DaretoBeam
Beam Therapeutics
Biotechnology Research
Cambridge, Massachusetts 82,882 followers
Our vision is to provide life-long cures for patients suffering from serious diseases.
About us
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening with open minds • Committed to each other
- Website
-
http://beamtx.com
External link for Beam Therapeutics
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2017
- Specialties
- gene therapy, base editing, gene editing, precision medicines, CRISPR, CRISPR Cas9, genetic diseases, rare diseases, hematology, lipid nanoparticles, LNP, vector production, AAV, In vivo, ex vivo, Liver, mRNA Production, mRNA, DNA, RNA, Cas9, drug development, drug delivery, immunology, formulation development, virology, viral delivery, nanoparticles formulation, structural biology, cell biology, protein sciences, and cell therapy
Locations
-
Primary
Get directions
238 Main St
Cambridge, Massachusetts 02142, US
Employees at Beam Therapeutics
Updates
-
Today is European Alpha-1 Awareness Day, an opportunity to advocate for better care, earlier diagnosis, and improved treatment access for #Alpha1 patients. Although Alpha-1 is most often seen in people of European ancestry, proper diagnosis is a global challenge. We encourage you to listen to Heather’s story to learn more about what it’s like to live with this genetic disease: https://lnkd.in/eNjf4dck
Living with Alpha-1: Heather's Story
https://www.youtube.com/
-
When manufacturing cell-based therapies that adhere to regulatory requirements and meet therapeutic needs of patients, cell therapy process development is crucial. Want to learn more? Watch our latest edition of #ScienceSimplified with Senior Research Associates Brianna McCuaig and Kathryn Goldner. #BeamTeam #DaretoBeam
-
The #BeamTeam is seeking dynamic, visionary, and strategic professionals to join our growing Medical Affairs team. Think you could be a good fit? Learn more about the open roles and apply here: https://beamtx.com/jobs/
-
-
Between the beautiful weather, Durham Bulls win, and team bonding, our North Carolina #BeamTeam outing was a home run! #DaretoBeam
-
-
We were thrilled to participate in the Life Science Cares Boston Impact Breakfast this week, and were honored to have been recognized for our long-standing partnership. Congratulations to LSC on 10 years of creating lasting change for our community! #DaretoBeam #BeamTeam
-
-
We’re proud to be named as a winner of Triangle Business Journal's 2026 Life Sciences Awards! Thank you to the #BeamTeam in Durham, NC for your hard work, focus, and commitment to our patients every day. #DaretoBeam Read the article for the full list: https://lnkd.in/eKJi2H6g
-
-
We had a great time at our recent internal speed networking event hosted in Cambridge, MA & Durham, NC! As the #BeamTeam grows, we love to have opportunities to build new relationships and learn from each other. #DaretoBeam
-
-
Beam’s Chief Medical Officer, Amy Simon, will be moderating a panel on “Accelerating Clinical Development with Adaptive Trial Approaches” at #CMOSummit360. We’re looking forward to the conversation on how adaptive trial strategies can help de‑risk clinical development and advance innovative therapies safely and efficiently to patients.
-
-
Today, Beam announced the publication of data from the ongoing Phase 1/2 BEACON clinical trial evaluating ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) for the treatment of sickle cell disease with severe vaso-occlusive crises in The New England Journal of Medicine. Read the press release here: https://lnkd.in/emCjua4Y #BeamTeam #DaretoBeam
-